Jacob Alexander Sloane, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 23 | 2024 | 3079 | 2.790 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 9 | 2021 | 520 | 1.890 |
Why?
|
| Myelin Sheath | 9 | 2023 | 655 | 1.470 |
Why?
|
| Immunologic Factors | 5 | 2022 | 1582 | 1.200 |
Why?
|
| Oligodendroglia | 6 | 2013 | 519 | 0.890 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2021 | 32 | 0.800 |
Why?
|
| Herpes Zoster | 1 | 2023 | 264 | 0.760 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 6 | 2021 | 236 | 0.730 |
Why?
|
| JC Virus | 2 | 2018 | 85 | 0.670 |
Why?
|
| Neuromyelitis Optica | 1 | 2022 | 253 | 0.630 |
Why?
|
| Lymphopenia | 1 | 2019 | 285 | 0.590 |
Why?
|
| Neuralgia | 1 | 2023 | 572 | 0.590 |
Why?
|
| Biotin | 1 | 2016 | 253 | 0.540 |
Why?
|
| Endometriosis | 1 | 2023 | 839 | 0.530 |
Why?
|
| Immunosuppressive Agents | 4 | 2023 | 4151 | 0.520 |
Why?
|
| Bariatric Surgery | 1 | 2023 | 952 | 0.460 |
Why?
|
| Drug Substitution | 1 | 2016 | 281 | 0.460 |
Why?
|
| Wiskott-Aldrich Syndrome Protein Family | 2 | 2007 | 37 | 0.380 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 2569 | 0.360 |
Why?
|
| Lymphocyte Count | 2 | 2023 | 793 | 0.340 |
Why?
|
| Nerve Degeneration | 3 | 2017 | 748 | 0.330 |
Why?
|
| Cerebral Cortex | 7 | 2019 | 5709 | 0.320 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2010 | 354 | 0.310 |
Why?
|
| Myosin Type V | 1 | 2007 | 34 | 0.310 |
Why?
|
| Antibodies, Viral | 1 | 2018 | 3176 | 0.290 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2018 | 135 | 0.290 |
Why?
|
| Hyaluronic Acid | 1 | 2010 | 491 | 0.290 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 592 | 0.270 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2007 | 443 | 0.270 |
Why?
|
| Myosin Heavy Chains | 1 | 2007 | 414 | 0.270 |
Why?
|
| Registries | 1 | 2021 | 8090 | 0.260 |
Why?
|
| Disability Evaluation | 4 | 2023 | 1828 | 0.260 |
Why?
|
| Disease Progression | 4 | 2023 | 13280 | 0.260 |
Why?
|
| Demyelinating Diseases | 2 | 2018 | 363 | 0.250 |
Why?
|
| Morphogenesis | 2 | 2007 | 752 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2024 | 35423 | 0.220 |
Why?
|
| Calpain | 1 | 2003 | 150 | 0.210 |
Why?
|
| Nerve Fibers, Myelinated | 3 | 2015 | 960 | 0.200 |
Why?
|
| Hospitalization | 1 | 2021 | 10262 | 0.200 |
Why?
|
| Cladribine | 1 | 2021 | 34 | 0.200 |
Why?
|
| Aging | 4 | 2003 | 8661 | 0.190 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2021 | 42 | 0.190 |
Why?
|
| Toluidines | 1 | 2020 | 19 | 0.190 |
Why?
|
| Crotonates | 1 | 2020 | 19 | 0.190 |
Why?
|
| Actins | 1 | 2007 | 2121 | 0.180 |
Why?
|
| Peptide Hydrolases | 1 | 2003 | 633 | 0.170 |
Why?
|
| Cerebrum | 1 | 2021 | 137 | 0.170 |
Why?
|
| Meninges | 1 | 2020 | 190 | 0.170 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2000 | 528 | 0.160 |
Why?
|
| New England | 1 | 2021 | 1022 | 0.160 |
Why?
|
| Neurobehavioral Manifestations | 1 | 1997 | 10 | 0.160 |
Why?
|
| Nitrates | 1 | 1999 | 265 | 0.150 |
Why?
|
| Stem Cells | 1 | 2010 | 3567 | 0.140 |
Why?
|
| HIV-2 | 1 | 2017 | 167 | 0.140 |
Why?
|
| Humans | 38 | 2024 | 744220 | 0.140 |
Why?
|
| Nerve Fibers | 1 | 2000 | 688 | 0.140 |
Why?
|
| Fatigue | 1 | 2023 | 1531 | 0.140 |
Why?
|
| Brain | 11 | 2024 | 26413 | 0.140 |
Why?
|
| Hematologic Tests | 1 | 2016 | 240 | 0.130 |
Why?
|
| Female | 28 | 2023 | 380197 | 0.130 |
Why?
|
| Thalamus | 2 | 2020 | 1024 | 0.130 |
Why?
|
| Social Adjustment | 1 | 2017 | 631 | 0.130 |
Why?
|
| Microglia | 2 | 2023 | 1266 | 0.130 |
Why?
|
| Immunoglobulins | 1 | 2018 | 881 | 0.130 |
Why?
|
| Receptors, GABA | 1 | 2016 | 288 | 0.130 |
Why?
|
| Adult | 20 | 2021 | 214035 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2016 | 23337 | 0.120 |
Why?
|
| Immunity | 1 | 2021 | 1012 | 0.120 |
Why?
|
| Male | 27 | 2021 | 350027 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2019 | 3328 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2023 | 77426 | 0.120 |
Why?
|
| Macaca mulatta | 4 | 2003 | 2378 | 0.110 |
Why?
|
| Plaque, Amyloid | 1 | 1997 | 729 | 0.110 |
Why?
|
| Astrocytes | 1 | 2000 | 1270 | 0.110 |
Why?
|
| Middle Aged | 17 | 2021 | 213367 | 0.100 |
Why?
|
| Weight Loss | 1 | 2023 | 2622 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2023 | 40559 | 0.100 |
Why?
|
| Risk Factors | 4 | 2021 | 72280 | 0.100 |
Why?
|
| Glucuronidase | 1 | 2013 | 207 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2013 | 8302 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2023 | 4385 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 2886 | 0.090 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2010 | 133 | 0.090 |
Why?
|
| Mortality | 1 | 2021 | 2864 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 4477 | 0.090 |
Why?
|
| Vitamin D | 1 | 2023 | 3222 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 4465 | 0.090 |
Why?
|
| Recurrence | 2 | 2021 | 8343 | 0.080 |
Why?
|
| Immunity, Innate | 2 | 2011 | 2958 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2021 | 8321 | 0.080 |
Why?
|
| Vesicle-Associated Membrane Protein 2 | 1 | 2007 | 19 | 0.080 |
Why?
|
| Positron-Emission Tomography | 3 | 2023 | 6274 | 0.080 |
Why?
|
| Executive Function | 1 | 2016 | 1362 | 0.080 |
Why?
|
| Phagocytes | 1 | 2009 | 297 | 0.080 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2007 | 91 | 0.070 |
Why?
|
| Comorbidity | 1 | 2021 | 10387 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2017 | 2576 | 0.070 |
Why?
|
| Growth Inhibitors | 1 | 2007 | 385 | 0.070 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2006 | 90 | 0.070 |
Why?
|
| Inflammation | 3 | 2019 | 10634 | 0.070 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2010 | 571 | 0.070 |
Why?
|
| Rats | 4 | 2013 | 24273 | 0.070 |
Why?
|
| Nerve Net | 1 | 2018 | 2175 | 0.070 |
Why?
|
| Emotions | 1 | 2017 | 2659 | 0.070 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 822 | 0.070 |
Why?
|
| Axons | 2 | 2017 | 1686 | 0.060 |
Why?
|
| Necrosis | 1 | 2009 | 1643 | 0.060 |
Why?
|
| Animals | 12 | 2013 | 168788 | 0.060 |
Why?
|
| Central Nervous System Diseases | 1 | 2009 | 518 | 0.060 |
Why?
|
| Central Nervous System | 2 | 2009 | 1357 | 0.060 |
Why?
|
| Neuroglia | 1 | 2010 | 927 | 0.060 |
Why?
|
| Neurites | 1 | 2006 | 388 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2016 | 2940 | 0.060 |
Why?
|
| Uric Acid | 1 | 2009 | 765 | 0.060 |
Why?
|
| Neural Inhibition | 1 | 2007 | 602 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 15538 | 0.060 |
Why?
|
| 2',3'-Cyclic-Nucleotide Phosphodiesterases | 1 | 2003 | 8 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2016 | 12035 | 0.050 |
Why?
|
| Age Factors | 1 | 2019 | 18367 | 0.050 |
Why?
|
| Ligands | 1 | 2009 | 3294 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3132 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3239 | 0.050 |
Why?
|
| Apoptosis | 2 | 2009 | 9728 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2019 | 12718 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 1741 | 0.050 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2021 | 27 | 0.050 |
Why?
|
| Cerebral Ventricles | 1 | 2024 | 544 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2010 | 2504 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2013 | 8437 | 0.050 |
Why?
|
| Tablets | 1 | 2021 | 147 | 0.050 |
Why?
|
| Cells, Cultured | 4 | 2013 | 19227 | 0.050 |
Why?
|
| Hydroxybutyrates | 1 | 2020 | 83 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2007 | 3001 | 0.050 |
Why?
|
| Quality of Life | 2 | 2021 | 12805 | 0.050 |
Why?
|
| Gliosis | 1 | 2000 | 245 | 0.040 |
Why?
|
| Blotting, Western | 3 | 2006 | 5180 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2011 | 23404 | 0.040 |
Why?
|
| Prospective Studies | 6 | 2021 | 53280 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2000 | 569 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 9735 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 1999 | 396 | 0.040 |
Why?
|
| Mice | 6 | 2013 | 81178 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 1999 | 645 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 21752 | 0.040 |
Why?
|
| Austria | 1 | 2017 | 203 | 0.040 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2017 | 66 | 0.040 |
Why?
|
| Serum Amyloid A Protein | 1 | 1997 | 121 | 0.040 |
Why?
|
| Bell Palsy | 1 | 2017 | 42 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2009 | 2400 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2013 | 14556 | 0.040 |
Why?
|
| Aged | 6 | 2020 | 163253 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 1999 | 916 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 1677 | 0.030 |
Why?
|
| Atrophy | 1 | 2020 | 1582 | 0.030 |
Why?
|
| Gadolinium | 1 | 2020 | 952 | 0.030 |
Why?
|
| Family Relations | 1 | 2017 | 321 | 0.030 |
Why?
|
| Nitriles | 1 | 2020 | 952 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 21824 | 0.030 |
Why?
|
| Tyrosine | 1 | 1999 | 1461 | 0.030 |
Why?
|
| Apolipoproteins | 1 | 1997 | 316 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2020 | 4044 | 0.030 |
Why?
|
| Anisotropy | 1 | 2017 | 1265 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2017 | 651 | 0.030 |
Why?
|
| Brain Chemistry | 1 | 1997 | 982 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 3871 | 0.030 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 1999 | 1121 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2021 | 3913 | 0.030 |
Why?
|
| Young Adult | 4 | 2021 | 56436 | 0.030 |
Why?
|
| Interferon-beta | 1 | 2014 | 323 | 0.030 |
Why?
|
| Polyomavirus Infections | 1 | 2014 | 197 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2018 | 63119 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2013 | 320 | 0.030 |
Why?
|
| Self Concept | 1 | 2017 | 1025 | 0.030 |
Why?
|
| HIV Infections | 1 | 2017 | 16718 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 1999 | 1901 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2018 | 8950 | 0.020 |
Why?
|
| Neurons | 2 | 2007 | 9335 | 0.020 |
Why?
|
| Optic Nerve | 1 | 2013 | 556 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2018 | 6367 | 0.020 |
Why?
|
| Cell Count | 1 | 2013 | 1854 | 0.020 |
Why?
|
| Corpus Callosum | 1 | 2013 | 737 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2014 | 2374 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2014 | 2226 | 0.020 |
Why?
|
| Alzheimer Disease | 2 | 1999 | 8037 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 39045 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 2737 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2007 | 982 | 0.020 |
Why?
|
| Neural Stem Cells | 1 | 2013 | 850 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2014 | 3203 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2006 | 252 | 0.020 |
Why?
|
| Amyloid beta-Peptides | 1 | 1997 | 3585 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1997 | 11368 | 0.010 |
Why?
|
| Sex Factors | 1 | 2017 | 10396 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2006 | 1799 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2017 | 4041 | 0.010 |
Why?
|
| Cell Survival | 1 | 2013 | 5881 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 1950 | 0.010 |
Why?
|
| Cognition | 1 | 1999 | 6765 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2006 | 2726 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2006 | 1701 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8387 | 0.010 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 1999 | 179 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2006 | 2501 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 1801 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 10182 | 0.010 |
Why?
|
| Time Factors | 2 | 2014 | 40063 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 57768 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2006 | 3617 | 0.010 |
Why?
|
| Child | 1 | 2021 | 77679 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 6313 | 0.010 |
Why?
|
| Transfection | 1 | 1999 | 5892 | 0.010 |
Why?
|
| United States | 1 | 2017 | 69867 | 0.010 |
Why?
|